Skip to main content
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Zentalis Pharmaceuticals, Inc. (ZNTL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysisthe core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Zentalis Pharmaceuticals, Inc.

ZNTL NASDAQ Categories PDF
Healthcare · Biotechnology
San Diego, CA 92121, United States IPO 2020 zentalis.com Updated Jul 18, 1:53am
Price
$5.11
Market Cap
$363.8M
Employees
106
Beta
1.93
Avg Volume
1,172,562
CEO
Julia Marie Eastland

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Runs with full report
Price Overview
Last updated: Jul 18, 2026 3:50am (just now)
Current data · timestamped when a report runs
$5.11
Change · Jul 18
+0.54 (+11.82%)
Day Range
$4.68 – $5.34
52-Week Range
$1.21 – $6.95
50-Day MA
$4.12
200-Day MA
$2.78
Volume
3,552,385.00
Analyst Price Targets
Low $10.00
Consensus $10.00
High $10.00
(14 analysts)
Share Structure
Outstanding 71,186,348.00
Float 48,556,208.00
Free Float 68.2%
Normal free float — 68.2% of shares trade freely, ~31.8% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History
Please log in to view the price history chart
The interactive 5-year price chart is a members feature — accounts are free.
Log in
Revenue & Net Income Trend
Please log in to view the revenue & earnings trend
Statement visualizations are a members feature — accounts are free.
Log in
Key Metrics
Please log in to view key metrics & ratios
The full valuation-ratio breakdown is a members feature — accounts are free.
Log in
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Financial Statements
Please log in to view the financial statements
Income statement, balance sheet, cash flow, estimates & dividends tables are a members feature — accounts are free.
Log in
Insider Trading
Please log in to view insider transactions
The insider buy/sell ledger is a members feature — accounts are free.
Log in
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ZNTL — it's generated by the pipeline (market-narrative step).
Community AI Feedback
No community reviews yet for ZNTL. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.436 · 3b9fc787 · 2026-07-17 20:58:07